Merger deal for TapImmune and Marker Therapeutics

TapImmune has entered into a definitive merger agreement to acquire Marker Therapeutics, a privately-held clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform. Read: Merger deal for TapImmune and Marker Therapeutics

Details